JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs

Molecular and Cellular Endocrinology

Volumn 451, Issue , 2017, Pages 88-96

  Cornez, Isabelle ^a   Yajnanarayana, Sowmya Parampalli ^a   Wolf, Anna Maria ^a   Wolf, Dominik ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Autoimmunity; GVHD; Immunosuppression; JAK; Myeloproliferative neoplasia; STAT

Indexed keywords

ADALIMUMAB; BARICITINIB; JANUS KINASE; JANUS KINASE INHIBITOR; MOMELOTINIB; RUXOLITINIB; STAT PROTEIN; TOFACITINIB; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; PROTEIN KINASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GAIN OF FUNCTION MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LOSS OF FUNCTION MUTATION; MALIGNANT NEOPLASM; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; NEOPLASM; ORGAN TRANSPLANTATION; PATHOLOGY;

AUTOIMMUNE DISEASES; CELL MOVEMENT; CYTOKINES; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASES; NEOPLASMS; ORGAN TRANSPLANTATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85011269329     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2017.01.035     Document Type: Article

References (109)

1. Amoako-Sakyi, D., Adukpo, S., Kusi, K.A., Dodoo, D., Ofori, M.F., Adjei, G.O., Edoh, D.E., Asmah, R.H., Brown, C., Adu, B., Obiri-Yeboah, D., Futagbi, G., Abubakari, S.B., Troye-Blomberg, M., Akanmori, B.D., Goka, B.Q., Arko-Mensah, J., Gyan, B.A., A STAT6 intronic single-nucleotide polymorphism is associated with clinical malaria in Ghanaian children. Genet. Epigenet 8 (2016), 7–14.
2. Amoli, M.M., Hand, S., Hajeer, A.H., Jones, K.P., Rolf, S., Sting, C., Davies, B.H., Ollier, W.E., Polymorphism in the STAT6 gene encodes risk for nut allergy. Genes Immun. 3 (2002), 220–224.
3. Antov, A., Yang, L., Vig, M., Baltimore, D., Van Parijs, L., Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J. Immunol. 171 (2003), 3435–3441.
4. Asshoff, M., Warr, M., Haschka, D., Tymoszuk, P., Petzer, V., Demetz, E., Maciejewski, P., Seifert, M., Nairz, M., Posch, W., Fowles, P., Weiss, G., Whitney, A., Theurl, I., The Jak1/Jak2 inhibitor momelotinib inhibits Alk2, decreases hepcidin production and ameliorates anemia of chronic disease (ACD) in rodents. Blood, 126, 2015, 538.
5. Baris, S., Alroqi, F., Kiykim, A., Karakoc-Aydiner, E., Ogulur, I., Ozen, A., Charbonnier, L.M., Bakir, M., Boztug, K., Chatila, T.A., Barlan, I.B., Severe early-onset combined immunodeficiency due to heterozygous gain-of-function mutations in STAT1. J. Clin. Immunol. 36 (2016), 641–648.
6. Bayer, A.L., Yu, A., Malek, T.R., Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells. J. Immunol. 178 (2007), 4062–4071.
7. Blazar, B.R., Murphy, W.J., Abedi, M., Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol. 12 (2012), 443–458.
8. Bluyssen, H.A., Levy, D.E., Stat2 is a transcriptional activator that requires sequence-specific contacts provided by stat1 and p48 for stable interaction with DNA. J. Biol. Chem. 272 (1997), 4600–4605.
9. Casanova, J.L., Holland, S.M., Notarangelo, L.D., Inborn errors of human JAKs and STATs. Immunity 36 (2012), 515–528.
10. Chapgier, A., Kong, X.F., Boisson-Dupuis, S., Jouanguy, E., Averbuch, D., Feinberg, J., Zhang, S.Y., Bustamante, J., Vogt, G., Lejeune, J., Mayola, E., de Beaucoudrey, L., Abel, L., Engelhard, D., Casanova, J.L., A partial form of recessive STAT1 deficiency in humans. J. Clin. Invest. 119 (2009), 1502–1514.
11. Choi, J., Cooper, M.L., Alahmari, B., Ritchey, J., Collins, L., Holt, M., DiPersio, J.F., Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One, 9, 2014, e109799.
12. Cirillo, E., Giardino, G., Gallo, V., D'Assante, R., Grasso, F., Romano, R., Di Lillo, C., Galasso, G., Pignata, C., Severe combined immunodeficiency–an update. Ann. N. Y. Acad. Sci. 1356 (2015), 90–106.
13. Cohen, A.C., Nadeau, K.C., Tu, W., Hwa, V., Dionis, K., Bezrodnik, L., Teper, A., Gaillard, M., Heinrich, J., Krensky, A.M., Rosenfeld, R.G., Lewis, D.B., Cutting edge: decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J. Immunol. 177 (2006), 2770–2774.
14. Davidson, T.S., DiPaolo, R.J., Andersson, J., Shevach, E.M., Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J. Immunol. 178 (2007), 4022–4026.
15. Deisseroth, A., Kaminskas, E., Grillo, J., Chen, W., Saber, H., Lu, H.L., Rothmann, M.D., Brar, S., Wang, J., Garnett, C., Bullock, J., Burke, L.B., Rahman, A., Sridhara, R., Farrell, A., Pazdur, R., U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin. Cancer Res. 18 (2012), 3212–3217.
16. Duetsch, G., Illig, T., Loesgen, S., Rohde, K., Klopp, N., Herbon, N., Gohlke, H., Altmueller, J., Wjst, M., STAT6 as an asthma candidate gene: polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study. Hum. Mol. Genet. 11 (2002), 613–621.
17. Dupuis, S., Dargemont, C., Fieschi, C., Thomassin, N., Rosenzweig, S., Harris, J., Holland, S.M., Schreiber, R.D., Casanova, J.L., Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293 (2001), 300–303.
18. Dupuis, S., Jouanguy, E., Al-Hajjar, S., Fieschi, C., Al-Mohsen, I.Z., Al-Jumaah, S., Yang, K., Chapgier, A., Eidenschenk, C., Eid, P., Al Ghonaium, A., Tufenkeji, H., Frayha, H., Al-Gazlan, S., Al-Rayes, H., Schreiber, R.D., Gresser, I., Casanova, J.L., Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet. 33 (2003), 388–391.
19. Ellinghaus, D., Ellinghaus, E., Nair, R.P., Stuart, P.E., Esko, T., Metspalu, A., Debrus, S., Raelson, J.V., Tejasvi, T., Belouchi, M., West, S.L., Barker, J.N., Koks, S., Kingo, K., Balschun, T., Palmieri, O., Annese, V., Gieger, C., Wichmann, H.E., Kabesch, M., Trembath, R.C., Mathew, C.G., Abecasis, G.R., Weidinger, S., Nikolaus, S., Schreiber, S., Elder, J.T., Weichenthal, M., Nothnagel, M., Franke, A., Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am. J. Hum. Genet. 90 (2012), 636–647.
20. Feldman, G.M., Rosenthal, L.A., Liu, X., Hayes, M.P., Wynshaw-Boris, A., Leonard, W.J., Hennighausen, L., Finbloom, D.S., STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 90 (1997), 1768–1776.
21. Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., Gruben, D., Wallenstein, G.V., Zwillich, S.H., Kanik, K.S., Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367 (2012), 495–507.
22. Fridman, J.S., Scherle, P.A., Collins, R., Burn, T.C., Li, Y., Li, J., Covington, M.B., Thomas, B., Collier, P., Favata, M.F., Wen, X., Shi, J., McGee, R., Haley, P.J., Shepard, S., Rodgers, J.D., Yeleswaram, S., Hollis, G., Newton, R.C., Metcalf, B., Friedman, S.M., Vaddi, K., Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 184 (2010), 5298–5307.
23. Gupta, V., Mesa, R.A., Deininger, M.W., Rivera, C.E., Sirhan, S., Brachmann, C.B., Collins, H., Kawashima, J., Xin, Y., Verstovsek, S., A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica 102 (2017), 94–102.
24. Hambleton, S., Goodbourn, S., Young, D.F., Dickinson, P., Mohamad, S.M., Valappil, M., McGovern, N., Cant, A.J., Hackett, S.J., Ghazal, P., Morgan, N.V., Randall, R.E., STAT2 deficiency and susceptibility to viral illness in humans. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 3053–3058.
25. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T., Barosi, G., JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366 (2012), 787–798.
26. Heine, A., Held, S.A., Daecke, S.N., Wallner, S., Yajnanarayana, S.P., Kurts, C., Wolf, D., Brossart, P., The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122 (2013), 1192–1202.
27. Hinks, A., Eyre, S., Ke, X., Barton, A., Martin, P., Flynn, E., Packham, J., Worthington, J., Thomson, W., Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis. Ann. Rheum. Dis. 69 (2010), 1049–1053.
28. Hwa, V., Nadeau, K., Wit, J.M., Rosenfeld, R.G., STAT5b deficiency: lessons from STAT5b gene mutations. Best. Pract. Res. Clin. Endocrinol. Metab. 25 (2011), 61–75.
29. Ihle, J.N., Cytokine receptor signalling. Nature 377 (1995), 591–594.
30. Imada, K., Bloom, E.T., Nakajima, H., Horvath-Arcidiacono, J.A., Udy, G.B., Davey, H.W., Leonard, W.J., Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J. Exp. Med. 188 (1998), 2067–2074.
31. Ishida, F., Matsuda, K., Sekiguchi, N., Makishima, H., Taira, C., Momose, K., Nishina, S., Senoo, N., Sakai, H., Ito, T., Kwong, Y.L., STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci. 105 (2014), 342–346.
32. Jerez, A., Clemente, M.J., Makishima, H., Koskela, H., Leblanc, F., Peng Ng, K., Olson, T., Przychodzen, B., Afable, M., Gomez-Segui, I., Guinta, K., Durkin, L., Hsi, E.D., McGraw, K., Zhang, D., Wlodarski, M.W., Porkka, K., Sekeres, M.A., List, A., Mustjoki, S., Loughran, T.P., Maciejewski, J.P., STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120 (2012), 3048–3057.
33. Jerez, A., Clemente, M.J., Makishima, H., Rajala, H., Gomez-Segui, I., Olson, T., McGraw, K., Przychodzen, B., Kulasekararaj, A., Afable, M., Husseinzadeh, H.D., Hosono, N., LeBlanc, F., Lagstrom, S., Zhang, D., Ellonen, P., Tichelli, A., Nissen, C., Lichtin, A.E., Wodnar-Filipowicz, A., Mufti, G.J., List, A.F., Mustjoki, S., Loughran, T.P. Jr., Maciejewski, J.P., STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood 122 (2013), 2453–2459.
34. Kaplan, M.H., Sun, Y.L., Hoey, T., Grusby, M.J., Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382 (1996), 174–177.
35. Kaplan, M.H., Schindler, U., Smiley, S.T., Grusby, M.J., Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4 (1996), 313–319.
36. Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., Pfeffer, K., Muller, M., Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13 (2000), 549–560.
37. Keles, S., Charbonnier, L.M., Kabaleeswaran, V., Reisli, I., Genel, F., Gulez, N., Al-Herz, W., Ramesh, N., Perez-Atayde, A., Karaca, N.E., Kutukculer, N., Wu, H., Geha, R.S., Chatila, T.A., Dedicator of cytokinesis 8 regulates signal transducer and activator of transcription 3 activation and promotes TH17 cell differentiation. J. Allergy Clin. Immunol. 138 (2016), 1384–1394 e2.
38. Kisand, K., Boe Wolff, A.S., Podkrajsek, K.T., Tserel, L., Link, M., Kisand, K.V., Ersvaer, E., Perheentupa, J., Erichsen, M.M., Bratanic, N., Meloni, A., Cetani, F., Perniola, R., Ergun-Longmire, B., Maclaren, N., Krohn, K.J., Pura, M., Schalke, B., Strobel, P., Leite, M.I., Battelino, T., Husebye, E.S., Peterson, P., Willcox, N., Meager, A., Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207 (2010), 299–308.
39. Kofoed, E.M., Hwa, V., Little, B., Woods, K.A., Buckway, C.K., Tsubaki, J., Pratt, K.L., Bezrodnik, L., Jasper, H., Tepper, A., Heinrich, J.J., Rosenfeld, R.G., Growth hormone insensitivity associated with a STAT5b mutation. N. Engl. J. Med. 349 (2003), 1139–1147.
40. Koskela, H.L., Eldfors, S., Ellonen, P., van Adrichem, A.J., Kuusanmaki, H., Andersson, E.I., Lagstrom, S., Clemente, M.J., Olson, T., Jalkanen, S.E., Majumder, M.M., Almusa, H., Edgren, H., Lepisto, M., Mattila, P., Guinta, K., Koistinen, P., Kuittinen, T., Penttinen, K., Parsons, A., Knowles, J., Saarela, J., Wennerberg, K., Kallioniemi, O., Porkka, K., Loughran, T.P. Jr., Heckman, C.A., Maciejewski, J.P., Mustjoki, S., Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med. 366 (2012), 1905–1913.
41. Kreins, A.Y., Ciancanelli, M.J., Okada, S., Kong, X.F., Ramirez-Alejo, N., Kilic, S.S., El Baghdadi, J., Nonoyama, S., Mahdaviani, S.A., Ailal, F., Bousfiha, A., Mansouri, D., Nievas, E., Ma, C.S., Rao, G., Bernasconi, A., Sun Kuehn, H., Niemela, J., Stoddard, J., Deveau, P., Cobat, A., El Azbaoui, S., Sabri, A., Lim, C.K., Sundin, M., Avery, D.T., Halwani, R., Grant, A.V., Boisson, B., Bogunovic, D., Itan, Y., Moncada-Velez, M., Martinez-Barricarte, R., Migaud, M., Deswarte, C., Alsina, L., Kotlarz, D., Klein, C., Muller-Fleckenstein, I., Fleckenstein, B., Cormier-Daire, V., Rose-John, S., Picard, C., Hammarstrom, L., Puel, A., Al-Muhsen, S., Abel, L., Chaussabel, D., Rosenzweig, S.D., Minegishi, Y., Tangye, S.G., Bustamante, J., Casanova, J.L., Boisson-Dupuis, S., Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 212 (2015), 1641–1662.
42. Lee, E.B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J.D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G.V., Zang, C., Zwillich, S.H., van Vollenhoven, R.F., Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370 (2014), 2377–2386.
43. Ling, Y., Cypowyj, S., Aytekin, C., Galicchio, M., Camcioglu, Y., Nepesov, S., Ikinciogullari, A., Dogu, F., Belkadi, A., Levy, R., Migaud, M., Boisson, B., Bolze, A., Itan, Y., Goudin, N., Cottineau, J., Picard, C., Abel, L., Bustamante, J., Casanova, J.L., Puel, A., Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J. Exp. Med. 212 (2015), 619–631.
44. Liu, L., Okada, S., Kong, X.F., Kreins, A.Y., Cypowyj, S., Abhyankar, A., Toubiana, J., Itan, Y., Audry, M., Nitschke, P., Masson, C., Toth, B., Flatot, J., Migaud, M., Chrabieh, M., Kochetkov, T., Bolze, A., Borghesi, A., Toulon, A., Hiller, J., Eyerich, S., Eyerich, K., Gulacsy, V., Chernyshova, L., Chernyshov, V., Bondarenko, A., Grimaldo, R.M., Blancas-Galicia, L., Beas, I.M., Roesler, J., Magdorf, K., Engelhard, D., Thumerelle, C., Burgel, P.R., Hoernes, M., Drexel, B., Seger, R., Kusuma, T., Jansson, A.F., Sawalle-Belohradsky, J., Belohradsky, B., Jouanguy, E., Bustamante, J., Bue, M., Karin, N., Wildbaum, G., Bodemer, C., Lortholary, O., Fischer, A., Blanche, S., Al-Muhsen, S., Reichenbach, J., Kobayashi, M., Rosales, F.E., Lozano, C.T., Kilic, S.S., Oleastro, M., Etzioni, A., Traidl-Hoffmann, C., Renner, E.D., Abel, L., Picard, C., Marodi, L., Boisson-Dupuis, S., Puel, A., Casanova, J.L., Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 208 (2011), 1635–1648.
45. Lundberg, P., Takizawa, H., Kubovcakova, L., Guo, G., Hao-Shen, H., Dirnhofer, S., Orkin, S.H., Manz, M.G., Skoda, R.C., Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J. Exp. Med. 211 (2014), 2213–2230.
46. McInnes, I.B., Schett, G., The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365 (2011), 2205–2219.
47. Meraz, M.A., White, J.M., Sheehan, K.C., Bach, E.A., Rodig, S.J., Dighe, A.S., Kaplan, D.H., Riley, J.K., Greenlund, A.C., Campbell, D., Carver-Moore, K., DuBois, R.N., Clark, R., Aguet, M., Schreiber, R.D., Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84 (1996), 431–442.
48. Milner, J.D., Brenchley, J.M., Laurence, A., Freeman, A.F., Hill, B.J., Elias, K.M., Kanno, Y., Spalding, C., Elloumi, H.Z., Paulson, M.L., Davis, J., Hsu, A., Asher, A.I., O'Shea, J., Holland, S.M., Paul, W.E., Douek, D.C., Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452 (2008), 773–776.
49. Milner, J.D., Vogel, T.P., Forbes, L., Ma, C.A., Stray-Pedersen, A., Niemela, J.E., Lyons, J.J., Engelhardt, K.R., Zhang, Y., Topcagic, N., Roberson, E.D., Matthews, H., Verbsky, J.W., Dasu, T., Vargas-Hernandez, A., Varghese, N., McClain, K.L., Karam, L.B., Nahmod, K., Makedonas, G., Mace, E.M., Sorte, H.S., Perminow, G., Rao, V.K., O'Connell, M.P., Price, S., Su, H.C., Butrick, M., McElwee, J., Hughes, J.D., Willet, J., Swan, D., Xu, Y., Santibanez-Koref, M., Slowik, V., Dinwiddie, D.L., Ciaccio, C.E., Saunders, C.J., Septer, S., Kingsmore, S.F., White, A.J., Cant, A.J., Hambleton, S., Cooper, M.A., Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125 (2015), 591–599.
50. Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pasic, S., Stojkovic, O., Metin, A., Karasuyama, H., Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448 (2007), 1058–1062.
51. Miossec, P., Kolls, J.K., Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11 (2012), 763–776.
52. Mogensen, T.H., STAT3 and the Hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. Jakstat, 2, 2013, e23435.
53. Moriggl, R., Gouilleux-Gruart, V., Jahne, R., Berchtold, S., Gartmann, C., Liu, X., Hennighausen, L., Sotiropoulos, A., Groner, B., Gouilleux, F., Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol. Cell Biol. 16 (1996), 5691–5700.
54. Murawski, M.R., Litherland, S.A., Clare-Salzler, M.J., Davoodi-Semiromi, A., Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann. N. Y. Acad. Sci. 1079 (2006), 198–204.
55. Nadeau, K., Hwa, V., Rosenfeld, R.G., STAT5b deficiency: an unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease. J. Pediatr. 158 (2011), 701–708.
56. Nakajima, H., Liu, X.W., Wynshaw-Boris, A., Rosenthal, L.A., Imada, K., Finbloom, D.S., Hennighausen, L., Leonard, W.J., An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction. Immunity 7 (1997), 691–701.
57. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., Pfeffer, K., Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93 (1998), 397–409.
58. Nguyen, K.B., Watford, W.T., Salomon, R., Hofmann, S.R., Pien, G.C., Morinobu, A., Gadina, M., O'Shea, J.J., Biron, C.A., Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297 (2002), 2063–2066.
59. Nosaka, T., van Deursen, J.M., Tripp, R.A., Thierfelder, W.E., Witthuhn, B.A., McMickle, A.P., Doherty, P.C., Grosveld, G.C., Ihle, J.N., Defective lymphoid development in mice lacking Jak3. Science 270 (1995), 800–802.
60. O'Shea, J.J., Holland, S.M., Staudt, L.M., JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368 (2013), 161–170.
61. Okiyama, N., Furumoto, Y., Villarroel, V.A., Linton, J.T., Tsai, W.L., Gutermuth, J., Ghoreschi, K., Gadina, M., O'Shea, J.J., Katz, S.I., Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J. Invest. Dermatol 134 (2014), 992–1000.
62. Ozaki, K., Spolski, R., Feng, C.G., Qi, C.F., Cheng, J., Sher, A., Morse, H.C. 3rd, Liu, C., Schwartzberg, P.L., Leonard, W.J., A critical role for IL-21 in regulating immunoglobulin production. Science 298 (2002), 1630–1634.
63. Parampalli Yajnanarayana, S., Stubig, T., Cornez, I., Alchalby, H., Schonberg, K., Rudolph, J., Triviai, I., Wolschke, C., Heine, A., Brossart, P., Kroger, N., Wolf, D., JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br. J. Haematol. 169 (2015), 824–833.
64. Pardanani, A., Harrison, C., Cortes, J.E., Cervantes, F., Mesa, R.A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A.M., Drummond, M.W., Jurgutis, M., Kuliczkowski, K., Gheorghita, E., Passamonti, F., Neumann, F., Patki, A., Gao, G., Tefferi, A., Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 1 (2015), 643–651.
65. Parganas, E., Wang, D., Stravopodis, D., Topham, D.J., Marine, J.C., Teglund, S., Vanin, E.F., Bodner, S., Colamonici, O.R., van Deursen, J.M., Grosveld, G., Ihle, J.N., Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93 (1998), 385–395.
66. Park, S.Y., Saijo, K., Takahashi, T., Osawa, M., Arase, H., Hirayama, N., Miyake, K., Nakauchi, H., Shirasawa, T., Saito, T., Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3 (1995), 771–782.
67. Park, C., Li, S., Cha, E., Schindler, C., Immune response in Stat2 knockout mice. Immunity 13 (2000), 795–804.
68. Passamonti, F., Vannucchi, A.M., Cervantes, F., Harrison, C., Morra, E., Kantarjian, H., Verstovsek, S., Ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia 29 (2014), 739–740.
69. Percy, M.J., McMullin, M.F., The V617F JAK2 mutation and the myeloproliferative disorders. Hematol. Oncol. 23 (2005), 91–93.
70. Polverelli, N., Breccia, M., Benevolo, G., Martino, B., Tieghi, A., Latagliata, R., Sabattini, E., Riminucci, M., Godio, L., Catani, L., Nicolosi, M., Perricone, M., Sollazzo, D., Colafigli, G., Campana, A., Merli, F., Vitolo, U., Alimena, G., Martinelli, G., Lewis, R.E., Vianelli, N., Cavo, M., Palandri, F., Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am. J. Hematol. 92 (2016), 37–41.
71. Prahalad, S., Hansen, S., Whiting, A., Guthery, S.L., Clifford, B., McNally, B., Zeft, A.S., Bohnsack, J.F., Jorde, L.B., Variants in TNFAIP3, STAT4, and C12orf30 loci associated with multiple autoimmune diseases are also associated with juvenile idiopathic arthritis. Arthritis Rheum. 60 (2009), 2124–2130.
72. Puel, A., Doffinger, R., Natividad, A., Chrabieh, M., Barcenas-Morales, G., Picard, C., Cobat, A., Ouachee-Chardin, M., Toulon, A., Bustamante, J., Al-Muhsen, S., Al-Owain, M., Arkwright, P.D., Costigan, C., McConnell, V., Cant, A.J., Abinun, M., Polak, M., Bougneres, P.F., Kumararatne, D., Marodi, L., Nahum, A., Roifman, C., Blanche, S., Fischer, A., Bodemer, C., Abel, L., Lilic, D., Casanova, J.L., Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207 (2010), 291–297.
73. Puel, A., Cypowyj, S., Bustamante, J., Wright, J.F., Liu, L., Lim, H.K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., Gumbleton, M., Toulon, A., Bodemer, C., El-Baghdadi, J., Whitters, M., Paradis, T., Brooks, J., Collins, M., Wolfman, N.M., Al-Muhsen, S., Galicchio, M., Abel, L., Picard, C., Casanova, J.L., Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332 (2011), 65–68.
74. Puel, A., Cypowyj, S., Marodi, L., Abel, L., Picard, C., Casanova, J.L., Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr. Opin. Allergy Clin. Immunol. 12 (2012), 616–622.
75. Rajala, H.L., Eldfors, S., Kuusanmaki, H., van Adrichem, A.J., Olson, T., Lagstrom, S., Andersson, E.I., Jerez, A., Clemente, M.J., Yan, Y., Zhang, D., Awwad, A., Ellonen, P., Kallioniemi, O., Wennerberg, K., Porkka, K., Maciejewski, J.P., Loughran, T.P. Jr., Heckman, C., Mustjoki, S., Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 121 (2013), 4541–4550.
76. Recher, M., Berglund, L.J., Avery, D.T., Cowan, M.J., Gennery, A.R., Smart, J., Peake, J., Wong, M., Pai, S.Y., Baxi, S., Walter, J.E., Palendira, U., Tangye, G.A., Rice, M., Brothers, S., Al-Herz, W., Oettgen, H., Eibel, H., Puck, J.M., Cattaneo, F., Ziegler, J.B., Giliani, S., Tangye, S.G., Notarangelo, L.D., IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in vivo. Blood 118 (2011), 6824–6835.
77. Remmers, E.F., Plenge, R.M., Lee, A.T., Graham, R.R., Hom, G., Behrens, T.W., de Bakker, P.I., Le, J.M., Lee, H.S., Batliwalla, F., Li, W., Masters, S.L., Booty, M.G., Carulli, J.P., Padyukov, L., Alfredsson, L., Klareskog, L., Chen, W.V., Amos, C.I., Criswell, L.A., Seldin, M.F., Kastner, D.L., Gregersen, P.K., STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357 (2007), 977–986.
78. Rodig, S.J., Meraz, M.A., White, J.M., Lampe, P.A., Riley, J.K., Arthur, C.D., King, K.L., Sheehan, K.C., Yin, L., Pennica, D., Johnson, E.M. Jr., Schreiber, R.D., Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93 (1998), 373–383.
79. Rudolph, J., Heine, A., Quast, T., Kolanus, W., Trebicka, J., Brossart, P., Wolf, D., The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. Leukemia 30 (2016), 2119–2123.
80. Saito, M., Nagasawa, M., Takada, H., Hara, T., Tsuchiya, S., Agematsu, K., Yamada, M., Kawamura, N., Ariga, T., Tsuge, I., Nonoyama, S., Karasuyama, H., Minegishi, Y., Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J. Exp. Med. 208 (2011), 235–249.
81. Schonberg, K., Rudolph, J., Vonnahme, M., Parampalli Yajnanarayana, S., Cornez, I., Hejazi, M., Manser, A.R., Uhrberg, M., Verbeek, W., Koschmieder, S., Brummendorf, T.H., Brossart, P., Heine, A., Wolf, D., JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 75 (2015), 2187–2199.
82. Schonberg, K., Rudolph, J., Yajnanarayana, S.P., Wolf, D., Get a grip on immune cells by inhibiting JAKs. Oncoimmunology, 5, 2016, e1071009.
83. Shimoda, K., van Deursen, J., Sangster, M.Y., Sarawar, S.R., Carson, R.T., Tripp, R.A., Chu, C., Quelle, F.W., Nosaka, T., Vignali, D.A., Doherty, P.C., Grosveld, G., Paul, W.E., Ihle, J.N., Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380 (1996), 630–633.
84. Snow, J.W., Abraham, N., Ma, M.C., Herndier, B.G., Pastuszak, A.W., Goldsmith, M.A., Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J. Immunol. 171 (2003), 5042–5050.
85. Sonnenberg, G.F., Fouser, L.A., Artis, D., Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12 (2011), 383–390.
86. Spoerl, S., Mathew, N.R., Bscheider, M., Schmitt-Graeff, A., Chen, S., Mueller, T., Verbeek, M., Fischer, J., Otten, V., Schmickl, M., Maas-Bauer, K., Finke, J., Peschel, C., Duyster, J., Poeck, H., Zeiser, R., von Bubnoff, N., Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 123 (2014), 3832–3842.
87. Tanaka, Y., Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. J. Biochem. 158 (2015), 173–179.
88. Tangye, S.G., Pillay, B., Randall, K.L., Avery, D.T., Phan, T.G., Gray, P., Ziegler, J.B., Smart, J.M., Peake, J., Arkwright, P.D., Hambleton, S., Orange, J., Goodnow, C.C., Uzel, G., Casanova, J.L., Lugo Reyes, S.O., Freeman, A.F., Su, H.C., Ma, C.S., Dedicator of cytokinesis 8-deficient CD4+ T cells are biased to a TH2 effector fate at the expense of TH1 and TH17 cells. J. Allergy Clin. Immunol., 2016 http://dx.doi.org/10.1016/j.jaci.2016.07.016. (epub ahead of print).
89. Thomis, D.C., Gurniak, C.B., Tivol, E., Sharpe, A.H., Berg, L.J., Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270 (1995), 794–797.
90. Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O.N., Xu, C.F., Neubert, T.A., Skoda, R.C., Hubbard, S.R., Silvennoinen, O., The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18 (2011), 971–976.
91. Uzel, G., Sampaio, E.P., Lawrence, M.G., Hsu, A.P., Hackett, M., Dorsey, M.J., Noel, R.J., Verbsky, J.W., Freeman, A.F., Janssen, E., Bonilla, F.A., Pechacek, J., Chandrasekaran, P., Browne, S.K., Agharahimi, A., Gharib, A.M., Mannurita, S.C., Yim, J.J., Gambineri, E., Torgerson, T., Tran, D.Q., Milner, J.D., Holland, S.M., Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J. Allergy Clin. Immunol. 131 (2013), 1611–1623.
92. van de Veerdonk, F.L., Plantinga, T.S., Hoischen, A., Smeekens, S.P., Joosten, L.A., Gilissen, C., Arts, P., Rosentul, D.C., Carmichael, A.J., Smits-van der Graaf, C.A., Kullberg, B.J., van der Meer, J.W., Lilic, D., Veltman, J.A., Netea, M.G., STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 365 (2011), 54–61.
93. Velazquez, L., Fellous, M., Stark, G.R., Pellegrini, S., A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70 (1992), 313–322.
94. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H. Jr., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V., Kantarjian, H.M., A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366 (2012), 799–807.
95. Verstovsek, S., Hoffman, R., Mascarenhas, J., Soria, J.C., Bahleda, R., McCoon, P., Tang, W., Cortes, J., Kantarjian, H., Ribrag, V., A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leuk. Res. 39 (2015), 157–163.
96. Verstovsek, S., Odenike, O., Singer, J.W., Granston, T., Al-Fayoumi, S., Deeg, H.J., Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J. Hematol. Oncol., 9, 2016, 137.
97. Villarino, A.V., Kanno, Y., Ferdinand, J.R., O'Shea, J.J., Mechanisms of Jak/STAT signaling in immunity and disease. J. Immunol. 194 (2015), 21–27.
98. van Vollenhoven, R.F., Fleischmann, R., Cohen, S., Lee, E.B., Garcia Meijide, J.A., Wagner, S., Forejtova, S., Zwillich, S.H., Gruben, D., Koncz, T., Wallenstein, G.V., Krishnaswami, S., Bradley, J.D., Wilkinson, B., Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367 (2012), 508–519.
99. Wesemann, D.R., Magee, J.M., Boboila, C., Calado, D.P., Gallagher, M.P., Portuguese, A.J., Manis, J.P., Zhou, X., Recher, M., Rajewsky, K., Notarangelo, L.D., Alt, F.W., Immature B cells preferentially switch to IgE with increased direct Smu to Sepsilon recombination. J. Exp. Med. 208 (2011), 2733–2746.
100. Wolf, D., von Lilienfeld-Toal, M., Wolf, A.M., Schleuning, M., von Bergwelt-Baildon, M., Held, S.A., Brossart, P., Novel treatment concepts for graft-versus-host disease. Blood 119 (2012), 16–25.
101. Worbs, T., Hammerschmidt, S.I., Forster, R., Dendritic cell migration in health and disease. Nat. Rev. Immunol. 17 (2016), 30–48.
102. Yamaoka, K., Janus kinase inhibitors for rheumatoid arthritis. Curr. Opin. Chem. Biol. 32 (2016), 29–33.
103. Yan, J., Li, B., Lin, B., Lee, P.T., Chung, T.H., Tan, J., Bi, C., Lee, X.T., Selvarajan, V., Ng, S.B., Yang, H., Yu, Q., Chng, W.J., EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood 128 (2016), 948–958.
104. Yao, Z., Kanno, Y., Kerenyi, M., Stephens, G., Durant, L., Watford, W.T., Laurence, A., Robinson, G.W., Shevach, E.M., Moriggl, R., Hennighausen, L., Wu, C., O'Shea, J.J., Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109 (2007), 4368–4375.
105. Yu, H., Pardoll, D., Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9 (2009), 798–809.
106. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., Saco, J., Homet Moreno, B., Mezzadra, R., Chmielowski, B., Ruchalski, K., Shintaku, I.P., Sanchez, P.J., Puig-Saus, C., Cherry, G., Seja, E., Kong, X., Pang, J., Berent-Maoz, B., Comin-Anduix, B., Graeber, T.G., Tumeh, P.C., Schumacher, T.N., Lo, R.S., Ribas, A., Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375 (2016), 819–829.
107. Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S.K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, F.S., Na, I.K., Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Lubbert, M., Wasch, R., Scheid, C., Stolzel, F., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graff, A., van der Velden, W., Huls, G., Mielke, S., Grigoleit, G.U., Kuball, J., Flynn, R., Ihorst, G., Du, J., Blazar, B.R., Arnold, R., Kroger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J., von Bubnoff, N., Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29 (2015), 2062–2068.
108. Zhang, Q., Davis, J.C., Lamborn, I.T., Freeman, A.F., Jing, H., Favreau, A.J., Matthews, H.F., Davis, J., Turner, M.L., Uzel, G., Holland, S.M., Su, H.C., Combined immunodeficiency associated with DOCK8 mutations. N. Engl. J. Med. 361 (2009), 2046–2055.
109. Zhou, T., Georgeon, S., Moser, R., Moore, D.J., Caflisch, A., Hantschel, O., Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia 28 (2013), 404–407.